Journal of Movement Disorders

Original Articles

Phenotypic spectrum of Progressive Supranuclear Palsy: Clinical study and APOE effect: Amina NASRI, Ikram SGHAIER, Anis NEJI, Alya GHARBI, Youssef ABIDA, Saloua MRABET, Amina GARGOURI, Mouna BEN DJEBARA, Imen KACEM, Riadh GOUIDER; Received September 9, 2023 Accepted January 30, 2024 Published online January 30, 2024; DOI: https://doi.org/10.14802/jmd.23178 [Accepted]

327 View
45 Download

Abstract PDF: Objectives
Progressive supranuclear palsy (PSP)is a rare neurodegenerative disorder encompassing several phenotypes with various motor and cognitive deficits.We aimed to study motor and cognitive characteristics across PSP phenotypes,and assess the influence of the Apolipoprotein E (APOE)gene variants on PSP phenotypic expression.
Materials and Methods
In 20-year-cross-sectional study, we retrospectively reviewed the charts of all patients classified as PSP and re-categorized them into phenotypes using the MDS-2017 criteria. Phenotypes were divided into three subgroups based on the clinical presentation during the first 3 years after symptoms’ onset, which defines the early disease stage:Richardson’s syndrome (PSP-RS), PSP-cortical (PSP-F+PSP-SL+PSP-CBS) and PSP-subcortical(PSP-P+PSP-PGF+PSP-PI+PSP-OM+PSP-C+PSP-PLS).Data on clinical and neuropsychological assessments were collected.Genotyping of APOE was performed using the RFLP-PCR and verified by Sanger sequencing.
Results
We included 112 PSP patients comprising 10 phenotypes classified into 48PSP-RS, 34PSP-cortical(17.6%PSP-CBS,9.4%PSP-F,8.2%PSP-SL)and 30 PSP-subcortical(11.6%PSP-P,8%PSP-PI, 2.6%PSP-OM,1.8%PSP-PGF,1.8%PSP-C,0.9%PSP-PLS) subgroups. PSP-RS cases had older age of onset(p=0.009)and more akinetic-rigid and levodopa resistant parkinsonism(p=0.006),while PSP-cortical cases had more tremor and asymmetric and/or levodopa responsive parkinsonism(p=0.025).Cognitive domains were significantly less altered among PSP-subcortical subgroup.Overall,PSP-APOEε4 carriers developed parkinsonism earlier (p=0.019),had earlier oculomotor dysfunction(p=0.052) and more altered cognitive profile.It was also associated with younger age of parkinsonism onset in PSP-RS phenotype(p=0.026).
Conclusion
This study demonstrated the wide phenotypic spectrum of PSP among Tunisians.Later disease onset and akinetic-rigid and levodopa resistant parkinsonism were the hallmarks of PSP-RS phenotype,while milder cognitive impairment was characteristic of PSP-subcortical subgroup.APOEε4 allele was associated to earlier parkinsonism and oculomotor dysfunction and seemed to play a role in defining a more altered cognitive profile in PSP patients.

Potential Link Between Cognition and Motor Reserve in Patients With Parkinson’s Disease: Seok Jong Chung, Yae Ji Kim, Yun Joong Kim, Hye Sun Lee, Mijin Yun, Phil Hyu Lee, Yong Jeong, Young H. Sohn; J Mov Disord. 2022;15(3):249-257. Published online September 7, 2022; DOI: https://doi.org/10.14802/jmd.22063

2,671 View
149 Download
3 Web of Science
3 Crossref

Objective
To investigate whether there is a link between cognitive function and motor reserve (i.e., individual capacity to cope with nigrostriatal dopamine depletion) in patients with newly diagnosed Parkinson’s disease (PD).
Methods
A total of 163 patients with drug-naïve PD who underwent ¹⁸F-FP-CIT PET, brain MRI, and a detailed neuropsychological test were enrolled. We estimated individual motor reserve based on initial motor deficits and striatal dopamine depletion using a residual model. We performed correlation analyses between motor reserve estimates and cognitive composite scores. Diffusion connectometry analysis was performed to map the white matter fiber tracts, of which fractional anisotropy (FA) values were well correlated with motor reserve estimates. Additionally, Cox regression analysis was used to assess the effect of initial motor reserve on the risk of dementia conversion.
Results
The motor reserve estimate was positively correlated with the composite score of the verbal memory function domain (γ = 0.246) and with the years of education (γ = 0.251). Connectometry analysis showed that FA values in the left fornix were positively correlated with the motor reserve estimate, while no fiber tracts were negatively correlated with the motor reserve estimate. Cox regression analysis demonstrated that higher motor reserve estimates tended to be associated with a lower risk of dementia conversion (hazard ratio, 0.781; 95% confidence interval, 0.576–1.058).
Conclusion
The present study demonstrated that the motor reserve estimate was well correlated with verbal memory function and with white matter integrity in the left fornix, suggesting a possible link between cognition and motor reserve in patients with PD.

Citations

Citations to this article as recorded by

Hippocampal Perfusion Affects Motor and Cognitive Functions in Parkinson Disease: An Early Phase 18F‐FP‐CIT Positron Emission Tomography Study
Min Young Chun, Seok Jong Chung, Su Hong Kim, Chan Wook Park, Seong Ho Jeong, Hye Sun Lee, Phil Hyu Lee, Young H. Sohn, Yong Jeong, Yun Joong Kim
Annals of Neurology.2024; 95(2): 388. CrossRef
Imaging Procedure and Clinical Studies of [18F]FP-CIT PET
Changhwan Sung, Seung Jun Oh, Jae Seung Kim
Nuclear Medicine and Molecular Imaging.2024;[Epub] CrossRef
Extra-Basal Ganglia Brain Structures Are Related to Motor Reserve in Parkinson’s Disease
Jinyoung Youn, Ji Hye Won, Mansu Kim, Junmo Kwon, Seung Hwan Moon, Minkyeong Kim, Jong Hyun Ahn, Jun Kyu Mun, Hyunjin Park, Jin Whan Cho
Journal of Parkinson's Disease.2023; 13(1): 39. CrossRef

Association between Olfactory Deficit and Motor and Cognitive Function in Parkinson’s Disease: Han Soo Yoo, Seok Jong Chung, Yang Hyun Lee, Byoung Seok Ye, Young H. Sohn, Phil Hyu Lee; J Mov Disord. 2020;13(2):133-141. Published online April 6, 2020; DOI: https://doi.org/10.14802/jmd.19082

9,934 View
280 Download
21 Web of Science
21 Crossref

Abstract PDF Supplementary Material

Objective
To investigate whether baseline olfactory dysfunction in Parkinson’s disease (PD) patients is associated with baseline and longitudinal motor and cognitive function.
Methods
We recruited 228 drug-naïve PD patients who were followed for a mean of 6 years. Patients underwent the Cross-Cultural Smell Identification Test (CCSIT), a neuropsychological test, and N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane positron emission tomography within 6 months of the baseline evaluation. Olfactory dysfunction was categorized as normosmia (CCSIT score ≥ 9), hyposmia (CCSIT score 5–8), and anosmia (CCSIT score ≤ 4). During the follow-up period, we investigated changes in the levodopa-equivalent dose (LED) and the occurrence of wearing-off, levodopa-induced dyskinesia, and dementia.
Results
Among the PD patients, 80.7% were hyposmic at the time of diagnosis, and 26.1% were anosmic. Baseline olfactory dysfunction was not associated with either initial parkinsonian motor symptoms or with the longitudinal LED increment and motor complications. Meanwhile, the anosmic group had lower baseline scores on the Korea version of the Boston Naming Test and Stroop color reading test than the normosmic and hyposmic groups. The anosmic group exhibited a higher rate of conversion to dementia than the normosmic [adjusted hazard ratio (HR) 3.99, 95% confidence interval (CI) 1.08–14.72] and hyposmic (adjusted HR 2.48, 95% CI 1.15–5.32) PD groups, regardless of baseline motor deficits and cognitive status.
Conclusion
Baseline olfactory dysfunction was not associated with motor deficits and complications, but it was associated with cognitive dysfunction and prognosis, suggesting that severe olfactory impairment may reflect early cortical involvement, probably in the frontotemporal region, and rapid spreading of Lewy body pathology.

Citations

Citations to this article as recorded by

Correlation of olfactory function factors with cardiac sympathetic denervation in Parkinson’s disease
Dong-Woo Ryu, Sang-Won Yoo, Ko-Eun Choi, Yoon-Sang Oh, Joong-Seok Kim
Journal of Neurology.2024; 271(3): 1397. CrossRef
Estimating motor progression trajectory pursuant to temporal dynamic status of cardiac denervation in Parkinson’s disease
Sang-Won Yoo, Dong-Woo Ryu, Yoon-Sang Oh, Seunggyun Ha, Chul Hyoung Lyoo, Yuna Kim, Ji-Yeon Yoo, Joong-Seok Kim
Journal of Neurology.2024; 271(4): 2019. CrossRef
Olfactory Dysfunction in Parkinson’s Disease, Its Functional and Neuroanatomical Correlates
Gabriel Torres-Pasillas, Donají Chi-Castañeda, Porfirio Carrillo-Castilla, Gerardo Marín, María Elena Hernández-Aguilar, Gonzalo Emiliano Aranda-Abreu, Jorge Manzo, Luis I. García
NeuroSci.2023; 4(2): 134. CrossRef
Impact of deep brain stimulation (DBS) on olfaction in Parkinson's disease: Clinical features and functional hypotheses
G. Brand, C. Bontempi, L. Jacquot
Revue Neurologique.2023; 179(9): 947. CrossRef
Sequential change in olfaction and (non) motor symptoms: the difference between anosmia and non-anosmia in Parkinson’s disease
Ting-Chun Fang, Yu-Shan Tsai, Ming-Hong Chang
Frontiers in Aging Neuroscience.2023;[Epub] CrossRef
Traumatic brain injury-induced inflammatory changes in the olfactory bulb disrupt neuronal networks leading to olfactory dysfunction
Xiang Liu, Zhuofan Lei, Dylan Gilhooly, Junyun He, Yun Li, Rodney M. Ritzel, Hui Li, Long-Jun Wu, Shaolin Liu, Junfang Wu
Brain, Behavior, and Immunity.2023; 114: 22. CrossRef
Serum Biomarkers of Olfactory Identification Deficits in Patients with Parkinson’s Disease
Fu-Jia Li, Yang-Dan-Yu Li, Xu Liu, Jie Zu, Wei Zhang, Qi-Hua Xiao, Xue-Bin Niu, Li Du, Chen-Chen Cui, Ru-Yu Zhang, Xiao-Qing He, Gui-Yun Cui, Chuan-Ying Xu, Dominic B. Fee
Acta Neurologica Scandinavica.2023; 2023: 1. CrossRef
UPSIT subitems may predict motor progression in Parkinson’s disease
Yu-Hsuan Lin, Ting-Chun Fang, Hsin-Bei Lei, Shih-Chi Chiu, Ming-Hong Chang, Yi-Jen Guo
Frontiers in Neurology.2023;[Epub] CrossRef
Olfactory dysfunction is associated with motor function only in tremor-dominant Parkinson’s disease
Fardin Nabizadeh, Kasra Pirahesh, Elham Khalili
Neurological Sciences.2022; 43(7): 4193. CrossRef
Novel diagnostic tools for identifying cognitive impairment using olfactory-stimulated functional near-infrared spectroscopy: patient-level, single-group, diagnostic trial
Jaewon Kim, Dong Keon Yon, Kyu Yeong Choi, Jang Jae Lee, Namwoo Kim, Kun Ho Lee, Jae Gwan Kim
Alzheimer's Research & Therapy.2022;[Epub] CrossRef
The Role of Olfactory System in the Etiogenesis of Parkinson’s Diseases: An Overview
Jiju Narayanan Avanipully, Dithu Thekkekkara, Sahyadri M, Vipan K. Parihar, Santhepete Nanjundaiah Manjula
Journal of Pharmacology and Pharmacotherapeutics.2022; 13(1): 31. CrossRef
International consensus statement on allergy and rhinology: Olfaction
Zara M. Patel, Eric H. Holbrook, Justin H. Turner, Nithin D. Adappa, Mark W. Albers, Aytug Altundag, Simone Appenzeller, Richard M. Costanzo, Ilona Croy, Greg E. Davis, Puya Dehgani‐Mobaraki, Richard L. Doty, Valerie B. Duffy, Bradley J. Goldstein, David
International Forum of Allergy & Rhinology.2022; 12(4): 327. CrossRef
Does Olfactory Dysfunction Correlate with Disease Progression in Parkinson’s Disease? A Systematic Review of the Current Literature
Tommaso Ercoli, Carla Masala, Gianluca Cadeddu, Marcello Mario Mascia, Gianni Orofino, Angelo Fabio Gigante, Paolo Solla, Giovanni Defazio, Lorenzo Rocchi
Brain Sciences.2022; 12(5): 513. CrossRef
Olfactory dysfunction and striatal dopamine transporter binding in motor subtypes of Parkinson’s disease
Fardin Nabizadeh, Fatemeh Sodeifian, Kasra Pirahesh
Neurological Sciences.2022; 43(8): 4745. CrossRef
Olfaction and Executive Cognitive Performance: A Systematic Review
Vasudeva Murthy Challakere Ramaswamy, Peter William Schofield
Frontiers in Psychology.2022;[Epub] CrossRef
Nasal and Parotid Blood Pool Activity Is Significantly Correlated with Metabolic Syndrome Components and Sleep Apnea
William T. Phillips, Nasser J. Issa, Shereef B. Elhalwagi, Hilda T. Draeger, Joyce G. Schwartz, Jonathan A. Gelfond
Metabolic Syndrome and Related Disorders.2022; 20(7): 395. CrossRef
Chronic neuropsychiatric sequelae of SARS‐CoV‐2: Protocol and methods from the Alzheimer's Association Global Consortium
Gabriel A. de Erausquin, Heather Snyder, Traolach S. Brugha, Sudha Seshadri, Maria Carrillo, Rajesh Sagar, Yueqin Huang, Charles Newton, Carmela Tartaglia, Charlotte Teunissen, Krister Håkanson, Rufus Akinyemi, Kameshwar Prasad, Giovanni D'Avossa, Gabriel
Alzheimer's & Dementia: Translational Research & Clinical Interventions.2022;[Epub] CrossRef
Machine learning-based prediction of cognitive outcomes in de novo Parkinson’s disease
Joshua Harvey, Rick A. Reijnders, Rachel Cavill, Annelien Duits, Sebastian Köhler, Lars Eijssen, Bart P. F. Rutten, Gemma Shireby, Ali Torkamani, Byron Creese, Albert F. G. Leentjens, Katie Lunnon, Ehsan Pishva
npj Parkinson's Disease.2022;[Epub] CrossRef
Impact of Subthalamic Deep Brain Stimulation on Hyposmia in Patients With Parkinson's Disease Is Influenced by Constipation and Dysbiosis of Microbiota
Chao Li, Ying Hou, Xu Wang, Yue-xuan Li, Feng Li, Chao Zhang, Wei-guo Li
Frontiers in Neurology.2021;[Epub] CrossRef
Hyposmia may predict development of freezing of gait in Parkinson’s disease
Jae Jung Lee, Jin Yong Hong, Jong Sam Baik
Journal of Neural Transmission.2021; 128(6): 763. CrossRef
Clinical and Dopamine Depletion Patterns in Hyposmia- and Dysautonomia-Dominant Parkinson’s Disease
Han Soo Yoo, Sangwon Lee, Seong Ho Jeong, Byoung Seok Ye, Young H. Sohn, Mijin Yun, Phil Hyu Lee
Journal of Parkinson's Disease.2021; 11(4): 1703. CrossRef

Cognition, Olfaction and Uric Acid in Early de novo Parkinson’s Disease: Hwa Reung Lee, Joong Hyun Park, Sang Won Han, Jong Sam Baik; J Mov Disord. 2018;11(3):139-144. Published online September 30, 2018; DOI: https://doi.org/10.14802/jmd.18037

6,674 View
149 Download
7 Web of Science
6 Crossref

Abstract PDF

Objective
Cognitive impairment is one of the nonmotor symptoms in Parkinson’s disease (PD), and olfactory dysfunction is used as a marker to detect premotor stages of PD. Serum uric acid (sUA) levels have been found to be a risk factor for PD. Our objective in this study was to examine whether sUA levels are associated with cognitive changes and olfactory dysfunction in early de novo PD patients.
Methods
The study participants included 196 de novo PD patients. We assessed cognitive function by the Korean versions of the Mini-Mental State Examination and the Montreal Cognitive Assessment and assessed olfactory function by the Korean version of the Sniffin’ Sticks test.
Results
The mean sUA level was 4.7 mg/dL and was significantly lower in women than in men. Cognitive scores were lower in women, suggesting that sUA levels were related to cognitive function. The olfactory functions were not related to sUA level but were clearly associated with cognitive scores. Olfactory threshold, odor discrimination, and odor identification were all significantly related to cognitive scores.
Conclusion
We conclude that lower sUA levels were associated with cognitive impairment, not olfactory dysfunction, in de novo PD patients. This finding suggests that UA is neuroprotective as an antioxidant in the cognitive function of PD patients.

Citations

Citations to this article as recorded by

Serum uric acid and Parkinson's disease: A systematic review and meta‐analysis
Mohammad Balabandian, Sarvenaz Salahi, Behnaz Mahmoudvand, Mahla Esmaeilzadeh, Seyedeh Melika Hashemi, Fardin Nabizadeh
Neurology and Clinical Neuroscience.2023; 11(6): 299. CrossRef
International consensus statement on allergy and rhinology: Olfaction
Zara M. Patel, Eric H. Holbrook, Justin H. Turner, Nithin D. Adappa, Mark W. Albers, Aytug Altundag, Simone Appenzeller, Richard M. Costanzo, Ilona Croy, Greg E. Davis, Puya Dehgani‐Mobaraki, Richard L. Doty, Valerie B. Duffy, Bradley J. Goldstein, David
International Forum of Allergy & Rhinology.2022; 12(4): 327. CrossRef
Association of serum uric acid and non-motor symptoms in Parkinson's disease: A cross-sectional study from a movement disorders clinic in Lagos, Nigeria
OlanikeA Odeniyi, OluwadamilolaO Ojo, IfedayoAdeola Odeniyi, NjidekaUlunma Okubadejo
Journal of Clinical Sciences.2022; 19(3): 104. CrossRef
A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson’s disease
Per Borghammer, Mie Kristine Just, Jacob Horsager, Casper Skjærbæk, Anna Raunio, Eloise H. Kok, Sara Savola, Shigeo Murayama, Yuko Saito, Liisa Myllykangas, Nathalie Van Den Berge
npj Parkinson's Disease.2022;[Epub] CrossRef
What substance P might tell us about the prognosis and mechanism of Parkinson's disease?
Paola Tirassa, Tommaso Schirinzi, Marcello Raspa, Massimo Ralli, Antonio Greco, Antonella Polimeni, Roberta Possenti, Nicola Biagio Mercuri, Cinzia Severini
Neuroscience & Biobehavioral Reviews.2021; 131: 899. CrossRef
Brain-First versus Gut-First Parkinson’s Disease: A Hypothesis
Per Borghammer, Nathalie Van Den Berge, Teus van Laar
Journal of Parkinson's Disease.2019; 9(s2): S281. CrossRef

Prospective Characterization of Cognitive Function in Typical and ‘Brainstem Predominant’Progressive Supranuclear Palsy Phenotypes: Young-Eun C Lee, David R Williams, Jacqueline F I Anderson; J Mov Disord. 2018;11(2):72-77. Published online May 30, 2018; DOI: https://doi.org/10.14802/jmd.17067

7,934 View
126 Download
7 Web of Science
7 Crossref

Abstract PDF

Objective
Clinicopathological studies over the last decade have broadened the clinical spectrum of progressive supranuclear palsy (PSP) to include several distinct clinical syndromes. We examined the cognitive profiles of patients with PSP-Richardson’s syndrome (PSP-RS) and two atypical ‘brainstem predominant’ PSP phenotypes (PSP-parkinsonism, PSP-P; and PSP-pure akinesia with gait freezing, PSP-PAGF) using a comprehensive neuropsychological battery.
Methods
Fourteen patients diagnosed as PSP-RS, three patients with PSP-P and four patients with PSP-PAGF were assessed using a comprehensive battery of neuropsychological tests.
Results
The typical PSP-RS subgroup demonstrated greater impairments in processing speed [t(19) = -4.10, p = 0.001 (d =1.66)] and executive function [t(19) = -2.63, p = 0.02 (d = 1.20)] compared to the ‘brainstem predominant’ PSP phenotype.
Conclusion
This is the first prospective study to demonstrate that PSP-RS and ‘brainstem predominant’ PSP phenotypes can be differentiated on cognitive grounds. These differences correspond with variations in pathological profiles reported in the literature.

Citations

Citations to this article as recorded by

Pathomechanisms of cognitive impairment in progressive supranuclear palsy
Kurt A. Jellinger
Journal of Neural Transmission.2023; 130(4): 481. CrossRef
Differential Diagnosis of Rare Subtypes of Progressive Supranuclear Palsy and PSP-Like Syndromes—Infrequent Manifestations of the Most Common Form of Atypical Parkinsonism
Patrycja Krzosek, Natalia Madetko, Anna Migda, Bartosz Migda, Dominika Jaguś, Piotr Alster
Frontiers in Aging Neuroscience.2022;[Epub] CrossRef
Clinical Spectrum of Tauopathies
Nahid Olfati, Ali Shoeibi, Irene Litvan
Frontiers in Neurology.2022;[Epub] CrossRef
Neuropsychological assessment could distinguish among different clinical phenotypes of progressive supranuclear palsy: A Machine Learning approach
Maria Grazia Vaccaro, Alessia Sarica, Andrea Quattrone, Carmelina Chiriaco, Maria Salsone, Maurizio Morelli, Aldo Quattrone
Journal of Neuropsychology.2021; 15(3): 301. CrossRef
“Parkinson’s disease” on the way to progressive supranuclear palsy: a review on PSP-parkinsonism
Ján Necpál, Miroslav Borsek, Bibiána Jeleňová
Neurological Sciences.2021; 42(12): 4927. CrossRef
The Progressive Supranuclear Palsy: Past and Present Aspects
Theodore P. Parthimos, Kleopatra H. Schulpis
Clinical Gerontologist.2020; 43(2): 155. CrossRef
Progressive Supranuclear Palsy—Parkinsonism Predominant (PSP-P)—A Clinical Challenge at the Boundaries of PSP and Parkinson's Disease (PD)
Piotr Alster, Natalia Madetko, Dariusz Koziorowski, Andrzej Friedman
Frontiers in Neurology.2020;[Epub] CrossRef

Cognition and Visit-to-Visit Variability of Blood Pressure and Heart Rate in De Novo Patients with Parkinson’s Disease: Kyum-Yil Kwon, Seon Jong Pyo, Hye Mi Lee, Woo-Keun Seo, Seong-Beom Koh; J Mov Disord. 2016;9(3):144-151. Published online September 21, 2016; DOI: https://doi.org/10.14802/jmd.16012

13,329 View
122 Download
8 Web of Science
8 Crossref

Abstract PDF Supplementary Material

Objective
We sought to identify whether the characteristics of long-term visit-to-visit blood pressure (BP) and heart rate (HR) are related to baseline cognitive profiles in, Parkinson’s disease (PD).
Methods
We selected drug-naïve PD patients who visited our hospital at least 10 times with a baseline assessment of the Seoul neuropsychological battery. BP and HR were measured at each visit, and the variability of the systolic BP/diastolic BP (DBP) and HR was derived from the parameters of serial 10 office visits. Mild cognitive impairment (MCI) in PD patients was determined according to the proposed criteria with a cut-off value of z-score ≤ -2.
Results
Forty-seven patients with PD (mean follow-up duration = 22.3 months) were enrolled in the study. Compared with non-MCI PD patients, MCI PD patients revealed a significant increase in HR and/or variability in DBP.
Conclusion
This exploratory study showed that baseline cognition in drug-naïve PD patients might be related to the visit-to-visit variability of DBP and/or HR.

Citations

Citations to this article as recorded by

Association between the blood pressure variability and cognitive decline in Parkinson's disease
Yi Xiao, Tianmi Yang, Lingyu Zhang, Qianqian Wei, Ruwei Ou, Yanbing Hou, Kuncheng Liu, Junyu Lin, Qirui Jiang, Huifang Shang
Brain and Behavior.2023;[Epub] CrossRef
Cardiovascular autonomic dysfunction is associated with executive dysfunction and poorer quality of life in progressive supranuclear palsy-Richardson’s syndrome
Peng Liu, Yueting Chen, Bo Wang, Sheng Wu, Leilei Zeng, Zhidong Cen, Dehao Yang, Haotian Wang, Xinhui Chen, Lebo Wang, Zhiyuan Ouyang, Wei Luo
Journal of Clinical Neuroscience.2022; 96: 147. CrossRef
Blood Pressure Variability and Cognitive Function: a Scoping Review
Nur Fazidah Asmuje, Sumaiyah Mat, Phyo Kyaw Myint, Maw Pin Tan
Current Hypertension Reports.2022; 24(10): 375. CrossRef
Associations of cognitive dysfunction with motor and non-motor symptoms in patients with de novo Parkinson’s disease
Kyum-Yil Kwon, Suyeon Park, Rae On Kim, Eun Ji Lee, Mina Lee
Scientific Reports.2022;[Epub] CrossRef
Blood pressure variability is related to faster cognitive decline in ischemic stroke patients: PICASSO subanalysis
Yerim Kim, Jae-Sung Lim, Mi Sun Oh, Kyung-Ho Yu, Ji Sung Lee, Jong-Ho Park, Yong-Jae Kim, Joung-Ho Rha, Yang-Ha Hwang, Sung Hyuk Heo, Seong Hwan Ahn, Ju-Hun Lee, Sun U. Kwon
Scientific Reports.2021;[Epub] CrossRef
The correlation of blood pressure variability and cognitive function in hypertension patients: A meta‐analysis
Xiaojie Jin, Yi Lu, Peng Zhao
International Journal of Clinical Practice.2021;[Epub] CrossRef
Burden and correlates of cognitive impairment among hypertensive patients in Tanzania: a cross-sectional study
Pedro Pallangyo, Zabella S. Mkojera, Makrina Komba, Lucy R. Mgopa, Smita Bhalia, Henry Mayala, Salma Wibonela, Nsajigwa Misidai, Happiness J. Swai, Jalack Millinga, Ester Chavala, Peter R. Kisenge, Mohamed Janabi
BMC Neurology.2021;[Epub] CrossRef
Backward Gait is Associated with Motor Symptoms and Fear of Falling in Patients withDe NovoParkinson's Disease
Kyum-Yil Kwon, Suyeon Park, Hye Mi Lee, Young-Min Park, Jinhee Kim, Jaehwan Kim, Seong-Beom Koh
Journal of Clinical Neurology.2019; 15(4): 473. CrossRef

Review Article

Cerebrospinal Fluid Amyloid β_1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson’s Disease: Ju-Hee Kang; J Mov Disord. 2016;9(2):89-96. Published online May 25, 2016; DOI: https://doi.org/10.14802/jmd.16017

20,053 View
243 Download
18 Web of Science
18 Crossref

Abstract PDF

Parkinson’s disease (PD) is a neurodegenerative disease with heterogeneous pathological and clinical features. Cognitive dysfunction, a frequent non-motor complication, is a risk factor for poor prognosis and shows inter-individual variation in its progression. Of the clinical studies performed to identify biomarkers of PD progression, the Parkinson’s Progression Markers Initiative (PPMI) study is the largest study that enrolled drug-naïve and very early stage PD patients. The baseline characteristics of the PPMI cohort were recently published. The diagnostic utility of cerebrospinal fluid (CSF) biomarkers, including alpha-synuclein (α-syn), total tau, phosphorylated tau at Thr₁₈₁, and amyloid β_1-42, was not satisfactory. However, the baseline data on CSF biomarkers in the PPMI study suggested that the measurement of the CSF biomarkers enables the prediction of future cognitive decline in PD patients, which was consistent with previous studies. To prove the hypothesis that the interaction between Alzheimer’s pathology and α-syn pathology is important to the progression of cognitive dysfunction in PD, longitudinal observational studies must be followed. In this review, the neuropathological nature of heterogeneous cognitive decline in PD is briefly discussed, followed by a summarized interpretation of baseline CSF biomarkers derived from the data in the PPMI study. The combination of clinical, biochemical, genetic and imaging biomarkers of PD constitutes a feasible strategy to predict the heterogeneous progression of PD.

Citations

Citations to this article as recorded by

Highly sensitive biosensor based on IGZO thin-film transistors for detection of Parkinson's disease
Tongzheng Li, Tongying Xu, Zhengyang Yao, Yanan Ding, Guoxia Liu, Fukai Shan
Applied Physics Letters.2023;[Epub] CrossRef
Extracellular vesicle biomarkers for cognitive impairment in Parkinson’s disease
Joseph Blommer, Toni Pitcher, Maja Mustapic, Erden Eren, Pamela J Yao, Michael P Vreones, Krishna A Pucha, John Dalrymple-Alford, Reza Shoorangiz, Wassilios G Meissner, Tim Anderson, Dimitrios Kapogiannis
Brain.2023; 146(1): 195. CrossRef
Imaging Biomarkers for Central Nervous System Drug Development and Future Clinical Utility: Lessons from Neurodegenerative Disorders
John P. Seibyl
Journal of Nuclear Medicine.2023; 64(1): 12. CrossRef
REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson’s disease: a cross-sectional and longitudinal study
Fardin Nabizadeh, Kasra Pirahesh, Parya Valizadeh
Journal of Neurology.2022; 269(9): 4836. CrossRef
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
Thomas Kremer, Kirsten I. Taylor, Juliane Siebourg‐Polster, Thomas Gerken, Andreas Staempfli, Christian Czech, Juergen Dukart, Douglas Galasko, Tatiana Foroud, Lana M. Chahine, Christopher S. Coffey, Tanya Simuni, Daniel Weintraub, John Seibyl, Kathleen L
Movement Disorders.2021; 36(8): 1972. CrossRef
Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis
J. M. Hatcher-Martin, J. L. McKay, A. F. Pybus, B. Sommerfeld, J. C. Howell, F. C. Goldstein, L. Wood, W. T. Hu, S. A. Factor
npj Parkinson's Disease.2021;[Epub] CrossRef
Melatonin affects the release of exosomes and tau-content in in vitro amyloid-beta toxicity model
Mehmet Ozansoy, Muzaffer Beyza Ozansoy, Burak Yulug, Seyda Cankaya, Ertugrul Kilic, Sule Goktekin, Ulkan Kilic
Journal of Clinical Neuroscience.2020; 73: 237. CrossRef
Disentangling the Amyloid Pathways: A Mechanistic Approach to Etiology
Maja Malmberg, Tarja Malm, Oskar Gustafsson, Andrea Sturchio, Caroline Graff, Alberto J. Espay, Anthony P. Wright, Samir El Andaloussi, Anders Lindén, Kariem Ezzat
Frontiers in Neuroscience.2020;[Epub] CrossRef
Why would Parkinson’s disease lead to sudden changes in creativity, motivation, or style with visual art?: A review of case evidence and new neurobiological, contextual, and genetic hypotheses
Jon O. Lauring, Tomohiro Ishizu, Hana H. Kutlikova, Felix Dörflinger, Steven Haugbøl, Helmut Leder, Ron Kupers, Matthew Pelowski
Neuroscience & Biobehavioral Reviews.2019; 100: 129. CrossRef
Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease
Tracy R. Melzer, Megan R. Stark, Ross J. Keenan, Daniel J. Myall, Michael R. MacAskill, Toni L. Pitcher, Leslie Livingston, Sophie Grenfell, Kyla-Louise Horne, Bob N. Young, Maddie J. Pascoe, Mustafa M. Almuqbel, Jian Wang, Steven H. Marsh, David H. Mille
Frontiers in Neurology.2019;[Epub] CrossRef
Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies
Kurt A. Jellinger
Journal of Neural Transmission.2018; 125(4): 615. CrossRef
Identification of a prospective early motor progression cluster of Parkinson's disease: Data from the PPMI study
George D. Vavougios, Triantafyllos Doskas, Constantinos Kormas, Karen A. Krogfelt, Sotirios G. Zarogiannis, Leonidas Stefanis
Journal of the Neurological Sciences.2018; 387: 103. CrossRef
Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease
Nooshin Abbasi, Bahram Mohajer, Sima Abbasi, Payam Hasanabadi, Amirhussein Abdolalizadeh, Reza Rajimehr
Movement Disorders.2018; 33(3): 431. CrossRef
Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
Mahsa Dolatshahi, Shayan Pourmirbabaei, Aida Kamalian, Amir Ashraf-Ganjouei, Mehdi Yaseri, Mohammad H. Aarabi
Frontiers in Neurology.2018;[Epub] CrossRef
Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study
Manuel Delgado‐Alvarado, Rosalía Dacosta‐Aguayo, Irene Navalpotro‐Gómez, Belén Gago, Ana Gorostidi, Haritz Jiménez‐Urbieta, Ana Quiroga‐Varela, Javier Ruiz‐Martínez, Alberto Bergareche, María C. Rodríguez‐Oroz
Movement Disorders.2018; 33(11): 1809. CrossRef
Extracellular Vesicles as a Source of Urological Biomarkers: Lessons Learned From Advances and Challenges in Clinical Applications to Major Diseases
Ji-Young Choi, Sujin Kim, Hyo-Bum Kwak, Dong-Ho Park, Jae-Hyoung Park, Jeong-Seon Ryu, Chang-Shin Park, Ju-Hee Kang
International Neurourology Journal.2017; 21(2): 83. CrossRef
Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease
Lori N. Eidson, George T. Kannarkat, Christopher J. Barnum, Jianjun Chang, Jaegwon Chung, Chelsea Caspell-Garcia, Peggy Taylor, Brit Mollenhauer, Michael G. Schlossmacher, Larry Ereshefsky, Mark Yen, Catherine Kopil, Mark Frasier, Kenneth Marek, Vicki S.
Journal of Neuroinflammation.2017;[Epub] CrossRef
Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias
Julie A Fields
Archives of Clinical Neuropsychology.2017; 32(7): 786. CrossRef

First
Prev
Page of 1
Next
Last

Search